Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 7477 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AYL, Chung ACK, Cheung CP, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DS-C, Chow KM, Ng SSS, Li TC-M, Ng RWY, Yip TCF, Wong GL-H, Chan FKL, Wong CK, Chan PKS, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2020:30 de diciembre. [Ref.ID 103837]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103830]
3. Cita con resumen
Weigand AJ, Bondi.MW, Thomas KR, Campbell NL, et al.. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology 2020;95:e2295-304. [Ref.ID 103815]
4.Tiene citas relacionadas Cita con resumen
Zhou J, Wang X, Lee S, Wu WKK, Cheung BMY, Zhang Q, Tse G. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut 2020:diciembre. [Ref.ID 103806]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton-pump inhibitors. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103795]
6. Cita con resumen
Zhang X-Y, Wu H-B, Ling Y, Qian Z-P, Chen L. Analysis of the effect of proton pump inhibitors on the course of common COVID-19. medRxiv 2020:13 de junio. [Ref.ID 103794]
7. Cita con resumen
Jimenez L, Campos Codo A, de Souza Sampaio V, Oliveira AER, Kobo Ferreira LK, Gastao Davanzo G, et al.. The influence of pH on SARS-CoV-2 infection and COVID-19 severity. medRxiv 2020:. [Ref.ID 103792]
8.Enlace a cita original Cita con resumen
Li G-F, An X-X, Yu Y, Jiao L-R, Canarutto D, Yu G, Wang G, Wu D-N, Xiao Y. Do proton pump inhibitors influence SARS-CoV- 2 related outcomes? A meta-analysis. Gut 2020:10 de noviembre. [Ref.ID 103790]
9. Cita con resumen
Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of fall eisk-increasing drugs around a fall-related injury in older adults: a systematic review. J Am Geriatr Soc 2020;68:junio. [Ref.ID 103662]
10. Cita con resumen
Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. Eur J Clin Pharmacol 2020;76:867-76. [Ref.ID 103644]
11. Cita con resumen
Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Hanson LC, Nace D, Thorpe JM, Thorpe CT. Risk for health events after deprescribing acetylcholinesterase inhibitors in nursing home residents with severe dementia. J Am Geriatr Soc 2020;68:699-707. [Ref.ID 103640]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, et al.. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103604]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103603]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]
15. Cita con resumen
Gandhi RT, Lynch JB, Del Río C. Mild or moderate Covid-19. N Engl J Med 2020:1. [Ref.ID 103596]
16.Enlace a cita original Cita con resumen
Zhang PZhi L, Cai J, Lei F, Qin J-J, Xie J, Liu Y-M, Zhao Y-C, Huang X, Lin L, Xia M, Chen M-M, Cheng X, Zhang X, Guo D, Peng Y, Ji Y-X, Chen J, She Z-G, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, et al.. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Research 2020;126:17 de abril. [Ref.ID 103594]
18. Cita con resumen
Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ 2020;368:27 de marzo. [Ref.ID 103583]
19. Cita con resumen
Seleccionar todas
 
 1 a 20 de 7477 siguiente >>